![Mary Canning](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mary Canning
Direttore/Membro del Consiglio presso Caldan Therapeutics Ltd.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Peter Finan | M | 57 |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.
Lunac Therapeutics Ltd.
![]() Lunac Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom.
Leucid Bio Ltd.
![]() Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023. | 10 anni |
Julian David Howell | M | 58 |
Lunac Therapeutics Ltd.
![]() Lunac Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom. | - |
Artin Moussavi | M | - |
Leucid Bio Ltd.
![]() Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023. | 5 anni |
Graeme Milligan | M | - |
Caldan Therapeutics Ltd.
![]() Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | - |
Helen Philippou | F | - |
Lunac Therapeutics Ltd.
![]() Lunac Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom. | 6 anni |
Filippo Petti | M | 52 |
Leucid Bio Ltd.
![]() Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023. | 1 anni |
Sarah L. Cole | M | - |
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 5 anni |
Elizabeth Ann Roper | M | 50 |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.
Caldan Therapeutics Ltd.
![]() Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | 11 anni |
Kyp Sirinakis | F | - |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | - |
Alan Keith Boyd | M | 70 |
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | - |
Andrew Dunlop | M | 52 |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | 14 anni |
Henning Steinhagen | M | - |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.
Caldan Therapeutics Ltd.
![]() Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | 5 anni |
Mark Payton | M | - |
Caldan Therapeutics Ltd.
![]() Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | 7 anni |
Trond Ulven | M | - |
Caldan Therapeutics Ltd.
![]() Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | - |
Terri Burke | F | - |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | 5 anni |
Anthony Voveris | M | - |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | 3 anni |
Robbie Woodman | M | 47 |
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | - |
Sarah Jane Jarmin | M | 50 |
Lunac Therapeutics Ltd.
![]() Lunac Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom. | - |
Miles Gerson | M | - |
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 3 anni |
Andy Billinton | M | - |
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 2 anni |
Paul Sekhri | M | 66 |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | - |
William R. Sellers | M | 63 |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | - |
Jan Thirkettle | M | - |
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 3 anni |
William Burns | M | 76 |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | - |
Christian Billy Jung | M | 42 |
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 4 anni |
John Savill | M | - |
The University of Edinburgh
| 26 anni |
Mervyn Turner | M | 77 |
Lunac Therapeutics Ltd.
![]() Lunac Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom. | - |
Michael Howard Jones | M | 59 |
Transine Therapeutics Ltd.
![]() Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | 6 anni |
Ian Alexander Francis Miscampbell | M | - |
Leucid Bio Ltd.
![]() Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023. | - |
Jeani Delagardelle | F | 67 |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | - |
Matthew Miessau | M | - |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | 10 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
David M. Lough | M | - |
The University of Edinburgh
| 7 anni |
Peng Hu | M | 48 |
The University of Edinburgh
| 3 anni |
Rob Brown | M | - |
The University of Edinburgh
| 6 anni |
Mark Andrew Urquhart | M | - |
The University of Edinburgh
| 3 anni |
D. Morrison | M | - |
The University of Edinburgh
| 4 anni |
Martin Payne | M | - |
The University of Edinburgh
| 4 anni |
James George MacDonald | M | - |
The University of Edinburgh
| 4 anni |
Michal Pechoucek | M | 52 |
The University of Edinburgh
| 1 anni |
George Prest | M | - |
The University of Edinburgh
| 4 anni |
Paul Barr | M | - |
The University of Edinburgh
| 4 anni |
Zhibin Xu | M | 48 |
The University of Edinburgh
| 1 anni |
Katherine Grass | F | - |
The University of Edinburgh
| 3 anni |
Alvin Loh | M | - |
The University of Edinburgh
| 4 anni |
Ya Nan Shen | M | 46 |
The University of Edinburgh
| 1 anni |
Wan Ip Min | M | - |
The University of Edinburgh
| 4 anni |
Sofia Maroudia | F | 47 |
The University of Edinburgh
| 1 anni |
James Cooke | M | - |
The University of Edinburgh
| 3 anni |
Zhi Bin Xu | M | 48 |
The University of Edinburgh
| 1 anni |
Rachel Haynes | F | - |
Epidarex Capital Partners LLC
![]() Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | - |
Georgios Halambalakis | M | 47 |
The University of Edinburgh
| 4 anni |
Marie Freier | F | - |
The University of Edinburgh
| 3 anni |
Charles Chipchase | M | - |
The University of Edinburgh
| 4 anni |
Sarah Ellis Davies | F | - |
The University of Edinburgh
| 3 anni |
Caroline Granshaw | F | - |
The University of Edinburgh
| 4 anni |
Kirsty MacCallum | F | - |
The University of Edinburgh
| 4 anni |
Andrew Harrison | M | - |
The University of Edinburgh
| 4 anni |
Sheldon Lee | M | - |
The University of Edinburgh
| 4 anni |
Duncan MacPherson | M | - |
The University of Edinburgh
| 4 anni |
Richard David Tennant | M | - |
The University of Edinburgh
| 4 anni |
Rosie Donachie | F | - |
The University of Edinburgh
| 4 anni |
Anastasia Papadopoulou | F | - |
The University of Edinburgh
| 2 anni |
Robert Morrish | M | - |
The University of Edinburgh
| 4 anni |
Timothy Stevenson | M | - |
The University of Edinburgh
| 4 anni |
Sabine Chalopin | F | - |
The University of Edinburgh
| 4 anni |
Damien Myles Ryder Maltwood | M | - |
The University of Edinburgh
| 4 anni |
Tómas Kristjánsson | M | 58 |
The University of Edinburgh
| 2 anni |
Tareq Mohammad Khalil Hammouri | M | 48 |
The University of Edinburgh
| 3 anni |
Guðmundur Jóhann Jónsson | M | - |
The University of Edinburgh
| 2 anni |
Shi Feng Ke | M | 59 |
The University of Edinburgh
| 2 anni |
James Wildash | M | - |
The University of Edinburgh
| 4 anni |
Angela Thornton-Jackson | F | - |
The University of Edinburgh
| 4 anni |
Joe D. Lewis | M | 57 |
The University of Edinburgh
| 5 anni |
Harry Draffan | M | - |
The University of Edinburgh
| 4 anni |
Tom Hopkins | M | - |
The University of Edinburgh
| - |
Camilla Sharples | F | - |
The University of Edinburgh
| 4 anni |
Alvaro Fernandez-Baca | M | - |
The University of Edinburgh
| 4 anni |
Alexander Leslie | M | 45 |
The University of Edinburgh
| 4 anni |
James Mills | M | - |
The University of Edinburgh
| 4 anni |
Timothy C. Tennent | M | - |
The University of Edinburgh
| 3 anni |
David Wedick | M | - |
The University of Edinburgh
| 4 anni |
Fareed Mohammed Hadi | M | 63 |
The University of Edinburgh
| 3 anni |
Randall O'Leary | M | - |
The University of Edinburgh
| 3 anni |
Alex Reynolds | M | - |
The University of Edinburgh
| 4 anni |
Aydin Kurt-Elli | M | - |
The University of Edinburgh
| 1 anni |
Richard Morrell | M | - |
The University of Edinburgh
| 4 anni |
Ian Andrew John Buchan | M | 43 |
The University of Edinburgh
| 4 anni |
Matthew Broome | M | - |
The University of Edinburgh
| 4 anni |
Spencer J. Jones | M | - |
The University of Edinburgh
| 4 anni |
Alasdair McKinnon | M | - |
The University of Edinburgh
| 4 anni |
Alistair David Smeaton | M | 43 |
The University of Edinburgh
| 4 anni |
Andy Murray | M | - |
The University of Edinburgh
| 4 anni |
Benjamin Gore | M | - |
The University of Edinburgh
| 1 anni |
Victoria Charlotte Caddick | F | - |
The University of Edinburgh
| 4 anni |
Zheng Ming Pan | M | 47 |
The University of Edinburgh
| 3 anni |
Calum Cusiter | M | 44 |
The University of Edinburgh
| 4 anni |
Mohamad Som bin Sujimon | M | 71 |
The University of Edinburgh
| 3 anni |
Suzana binti Sulaiman | M | 59 |
The University of Edinburgh
| 3 anni |
MILLS JAMES | M | - |
The University of Edinburgh
| 4 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 89 | 89.90% |
Stati Uniti | 13 | 13.13% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Mary Canning
- Contatti personali